Deal title Receiving grant Awarding grant Grant amount ($M) Date


NMSS to award Brainstorm funding for phase II clinical trial of NurOwn against progressive multiple sclerosis Brainstorm Cell Therapeutics Inc. National Multiple Sclerosis Society 0.50 11/14/19
Celyad to receives grants and non-dilutive funding by the Walloon region for the development of CAR-T cell therapy programs for relapsed/refractory acute myeloid leukemia Celyad SA Walloon Region of Belgium Government 9.45 11/22/19
SMA Europe to award funding to Fondazione IRCCS Ca' GrandaOspedale Maggiore Policlinico to identify the role of Stathmin-2 in spinal muscular atrophy Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico SMA Europe 0.17 11/8/19
NIAID to award Integral Molecular funding to develop vaccines and therapeutics for Zika, Marburg and EEV infections Integral Molecular Inc. National Institute of Allergy and Infectious Diseases 5.50 11/14/19
German state of Saxony to award funding to Mannin to discover, develop and commercialize therapeutics for glaucoma Mannin Research Inc. German Government 7.50 11/5/19
European Commission to award Maxivax funding for the phase II clinical trial of MVX-ONCO-1 against cancer Maxivax SA European Commission 3.10 11/27/19
NIH to award Northwestern University funding to develop DNA-based modified heat shock protein, HSP70i against vitiligo Northwestern University National Institutes of Health 4.50 11/20/19
Innovate UK to award Redx Pharma funding for validation and clinical development of biomarkers to assess Porcupine and ROCK2 inhibitors for IPF Redx Pharma plc Technology Strategy Board 0.64 11/19/19
Orion to award funding to University of Turku to conduct research on early onset dydregulation of vascular homeostasis in aortic aneurysms University of Turku Orion Corp 0.04 11/4/19
Alzheimer's Association to award Vaccinex funding to evaluate pepinemab in Alzheimer's Disease Vaccinex Inc. Alzheimer's Association 0.75 11/14/19

No Comments